The FDA moved to withdraw Tavneos (avacopan) from the US market after investigators found serious data-integrity issues in the pivotal trial that supported approval. The drug, developed by ChemoCentryx and later acquired by Amgen, had shown similar remission outcomes at 26 and 52 weeks versus standard of care plus placebo in the pivotal study, but the agency says unblinded personnel later manipulated results and the original analysis was not disclosed to the FDA.